KMT2C and neoplasm: A relatively high level of acquired alterations in RB1 (33%), the histone-lysine methyltransferase KMT2C (29%), and PTEN (19%) were also identified in the PD tumor samples, suggesting a role in driving resistance to therapy in this patient cohort (Fig. 4b).